期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Pembrolizumab对1例晚期非小细胞肺癌伴腹水的治疗报告 被引量：1

Short Term Efficacy of Pembrolizumab on Late-Stage Non-Small Cell Lung Cancer Accompanied by Ascites:a Case Report
下载PDF
导出
摘要 非小细胞肺癌（non-small cell lung cancer,NSCLC）占肺癌的80%~90%[1]。以铂类药物为主的化疗仅对的30%的NSCLC患者有效[2],还有部分患者不能耐受。Pembrolizumab是一种新型人源化单抗,其通过干扰程序性细胞死亡分子1（programmed death 1,PD-1）提升人体免疫力,主要用于治疗接受ipilimumab（伊匹单抗）治疗后不可切除的或转移性黑素瘤,
作者 丁玲 张伟华 余秉翔
机构地区 中国人民解放军总医院健康管理研究院国际部
出处 《中国临床医学》 2015年第5期692-693,共2页 Chinese Journal of Clinical Medicine
关键词 非小细胞肺癌 Pembrolizumab 转移性黑素瘤 铂类药物 programmed 程序性细胞死亡 人源化 吉非替尼 右上肺 血清肿瘤标记物
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献5

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
  • 2刘爱学,李明淑,周泽强,张容榕,金花,冯天举,谭淑瑜,李美香,林琳.多西他赛与吉西他滨分别联合顺铂治疗晚期非小细胞肺癌的临床疗效观察[J].海南医学,2013,24(2):171-173. 被引量：30
  • 3Pardoll DM. The block ade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4) : 252-264.
  • 4Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression[J]. Clin Cancer Res, 2004,10(15) :5094-5100.
  • 5Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475 anti-PD-1 monoclonal antibody) in patients with advanced solid tumors[J]. Clin Cancer Res, 2015, pii: cU ' canres. 2607. 2014.

二级参考文献13

  • 1The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors [J]. J Thorac Oncol, 2007, 2:706-714.
  • 2Azzoli CG, Baker S, Jr, Temin S, et al. American society of clinical on- eology clinical practice guideline update on ehemotherapy forstage IV non-small-cell lung cancer [J]. J Clin Oneol, 2009: 6251-6266.
  • 3NSCLC Meta-Analyses Collaborative Group. Chemotherapy in Addi- tion to supportive care improvessurvival lung cancer: a systematic review and meta-analysis of individual pa- tient data from 16 randomized controlled trials [J]. J Clin Oncol, 2008, 26: 4617-4625.
  • 4Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis [J]. Lancet, 1993, 342:19-21.
  • 5Goffin J, Lacchetti C, Ellis PM, et al. First-line systemic chemo- therapy in the treatment of advanced non-small lung cancer:a sys- tematic review [J]. J Thorac Oncol, 2010, 5(2): 260-274.
  • 6Schiller JH, Harrington D, Belani CP, et al. Comparison of four che- motherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med, 2002, 346: 92-98.
  • 7Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor ceils [J]. Anti cancer Drugs, 1992, 3: 121-124.
  • 8Kelland LR, Abel G.Comparative in vitro cytotoxicity of taxol and Tax- otere against cisplatin-sensitive and-resistant human ovarian carcino- ma cell lines [J]. Cancer Claemother Pharmacol, 1992, 30: 444-450.
  • 9Shord SS, Fancette SR, Gillenwater HH, et al. Gemcitabine pharmacoki- netics and interaction with paclitaxel in patients with advanced non-smaU cell lung cancer [J]. Cancer Chemother Pharmacol, 2003, 51(4): 328-336.
  • 10Sandier A, Nemunaitis J, Denham C. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advance or meta- static non-small cell lung cancer [J]. J Clin Oncol, 2000, 18: 122-130.

共引文献29

同被引文献4

引证文献1

二级引证文献7

中国临床医学
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部